If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that ...

Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced ...

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to ...

Both Agenus AGEN and Iovance Biotherapeutics IOVA are small-cap companies focused on next-generation cancer immunotherapies ...

Biotech stocks are attracting investors as M&A activity, valuations and upcoming catalysts help drive sector momentum.

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.

When Wall Street’s growth-at-any-price trade cools, capital tends to rotate toward profitable, cash-generative healthcare ...

This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified ...

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary ...